5 reports

  • Aug 14, 2017: Galena Biopharma Reports Second Quarter 2017 Financial Results
  • ACQUISITION

Product News ##/ ##/ 2017: Galena Biopharma Presents Positive Final GALE-## (E##) Phase ##/ ##a Clinical Trial Data Galena Biopharma, Inc., a biopharmaceutical company developing hematology and oncology therapeutics that address unmet medical needs, ann

  • Biopharmaceutical
  • Pharmaceutical
  • United States
  • Company
  • SELLAS Life Sciences Group
  • Aug 14, 2017: Galena Biopharma Reports Second Quarter 2017 Financial Results
  • ACQUISITION

Product News ##/ ##/ 2017: Galena Biopharma Presents Positive Final GALE-## (E##) Phase ##/ ##a Clinical Trial Data Galena Biopharma, Inc., a biopharmaceutical company developing hematology and oncology therapeutics that address unmet medical needs, ann

  • Biopharmaceutical
  • Pharmaceutical
  • United States
  • Company
  • SELLAS Life Sciences Group
  • Aug 14, 2017: Galena Biopharma Reports Second Quarter 2017 Financial Results
  • ACQUISITION

Product News ##/ ##/ 2017: Galena Biopharma Presents Positive Final GALE-## (E##) Phase ##/ ##a Clinical Trial Data Galena Biopharma, Inc., a biopharmaceutical company developing hematology and oncology therapeutics that address unmet medical needs, ann

  • Biopharmaceutical
  • Pharmaceutical
  • United States
  • Company
  • SELLAS Life Sciences Group
  • Scancell Holdings Plc

Galena Biopharma Inc changed its name to SELLAS Life Sciences Group Inc.

  • Biopharmaceutical
  • Cancer
  • Therapy
  • Vaccine
  • SELLAS Life Sciences Group
  • Galena Biopharma Acquires SELLAS Life Sciences
  • Sellas Life Sciences Enters into Licensing Agreement with Advaxis

It is a synthetic peptide vaccine consisting of the immunogenic amino acids of the human Wilms tumor protein-## peptides which include WT-## A##, WT-## ## long, WT-## ## long and WT-## ## long.

  • Biopharmaceutical
  • Medical Biotechnology
  • Pharmaceutical
  • United States
  • SELLAS Life Sciences Group